Donate

Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia

April 17, 2018

The following is an excerpt from a press release from Bioverativ. Read the entire press release here.  More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program Bioverativ Inc., a Sanofi company, joins the global hemophilia […]

CSL Behring Celebrates World Hemophilia Day

April 19, 2017

Global Drug Manufacturer CSL Behring announced last week it’s recognition of World Hemophilia Day by sharing news of a donation of more than 4 million international units (IUs) of its medicines to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program. To read the full release from CSL Behring, […]

Biogen Idec and Sobi To Donate $1 Billion Units of Clotting Factor

May 12, 2014

Biogen Idec and Swedish Orphan Biovitrum AB announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation […]

CSL Opens World-Class Manufacturing Facility for Hemophilia Therapies

May 9, 2014

CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is the centerpiece of CSL’s $250 million expansion at its Broadmeadows site and will play […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.